Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 97,500 shares, an increase of 9,650.0% from the August 15th total of 1,000 shares. Currently, 11.9% of the company’s stock are short sold. Based on an average daily volume of 272,700 shares, the short-interest ratio is currently 0.4 days.

Addex Therapeutics Stock Down 0.9 %

Shares of Addex Therapeutics stock opened at $10.21 on Friday. The company has a 50 day moving average price of $8.73 and a 200 day moving average price of $10.64. The firm has a market capitalization of $10.82 million, a P/E ratio of -0.59 and a beta of 1.79. Addex Therapeutics has a 52 week low of $5.00 and a 52 week high of $27.90.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Addex Therapeutics in a research note on Wednesday, August 28th.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.